Biomarkers
These videos have been matched automatically. Contact us if they are not relevant.
These videos have been matched automatically. Contact us if they are not relevant.
View abstract on PubMed
Summary
This summary is machine-generated.Speech changes appear before Alzheimer's disease (AD) diagnosis. Acoustic markers from story narration tasks show potential for early AD detection in preclinical and prodromal stages, aiding clinical trials.
Area Of Science
- Neurology
- Speech-language pathology
- Biomarkers
Background
- Alzheimer's disease (AD) is preceded by decades of speech and language changes.
- Digital tools for frequent speech assessments offer promise for early-stage AD clinical trials.
- The RADAR-AD study investigated acoustic speech markers from story narration tasks across different AD (ATN) stages.
Purpose Of The Study
- To evaluate the utility of acoustic speech markers for detecting early signs of Alzheimer's disease (AD).
- To analyze speech patterns in relation to amyloid (A), tau (T), and neurodegeneration (N) status within syndromic stages of AD.
- To assess the potential of speech markers in improving screening for AD clinical trials.
Main Methods
- Cross-sectional study with 159 participants across four groups: Healthy Controls (HC), preclinical AD (pre. AD), prodromal AD (pro. AD), and mild AD.
- Speech samples collected via a voice-based story narration task (Story Time) using the Mezurio smartphone application across 12 European languages.
- Linear mixed-effect models used to analyze speech data, considering participants, stories, and languages as random effects, and demographic variables as fixed effects.
Main Results
- Preclinical AD (A+T+) showed significantly lower articulation rates compared to controls.
- Prodromal AD (A+T+) also exhibited lower articulation rates, along with differences in speech rate, loudness, and vocalic features.
- Prodromal AD (A+T-) showed significant differences in jitter and voiced segments.
Conclusions
- Subtle, tau-driven changes in speech fluency are detectable as early as the preclinical stage of AD.
- Acoustic speech markers show potential for enhancing screening in AD clinical trials.
- This research was supported by the Innovative Medicines Initiative Joint Undertaking (grant No 806999).
These videos have been matched automatically. Contact us if they are not relevant.
These videos have been matched automatically. Contact us if they are not relevant.
Related Concept Videos
Cardiac biomarkers are enzymes, proteins, and hormones released into the blood when cardiac cells are injured. They are powerful tools for triaging.
The essential diagnostic tools for detecting myocardial necrosis and monitoring individuals suspected of having acute coronary syndrome (ACS) include:
Troponins
Troponins, particularly cardiac troponins I and T, are the most precise and sensitive markers of myocardial injury. They are detectable within 4-6 hours of myocardial injury and remain...
Cardiac biomarkers are critical in diagnosing, prognosing, and managing cardiovascular diseases. Routine measurement of specific biomarkers such as B-type natriuretic peptide (BNP), C-reactive protein (CRP), and homocysteine (Hcy) is common practice in clinical settings to evaluate heart function and predict cardiovascular events.
These markers indicate stress or strain on the heart muscle:
Natriuretic Peptides (BNP)
Cardiac myocytes produce these hormones in response to ventricular stretching...